17,105 Labcorp Holdings Inc. $LH Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its position in shares of Labcorp Holdings Inc. (NYSE:LH) by 355.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,921 shares of the medical research company’s stock after purchasing an additional 17,105 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Labcorp were worth $6,754,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Willis Investment Counsel lifted its position in Labcorp by 6.3% in the 3rd quarter. Willis Investment Counsel now owns 80,041 shares of the medical research company’s stock worth $24,661,000 after buying an additional 4,722 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Labcorp by 2.8% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 10,661 shares of the medical research company’s stock worth $3,285,000 after acquiring an additional 287 shares in the last quarter. CWA Asset Management Group LLC bought a new stake in shares of Labcorp during the 3rd quarter worth about $279,000. Richards Merrill & Peterson Inc. acquired a new position in shares of Labcorp during the 3rd quarter valued at about $228,000. Finally, Weybosset Research & Management LLC increased its holdings in shares of Labcorp by 0.5% during the 3rd quarter. Weybosset Research & Management LLC now owns 39,653 shares of the medical research company’s stock valued at $12,217,000 after acquiring an additional 214 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Activity at Labcorp

In other news, CEO Adam H. Schechter sold 4,669 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the completion of the sale, the chief executive officer directly owned 102,565 shares of the company’s stock, valued at $32,858,749.05. This represents a 4.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the sale, the executive vice president owned 6,956 shares in the company, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 8,593 shares of company stock worth $2,733,295 over the last ninety days. Company insiders own 0.84% of the company’s stock.

Labcorp Stock Performance

Shares of NYSE:LH opened at $329.10 on Friday. Labcorp Holdings Inc. has a twelve month low of $244.52 and a twelve month high of $341.80. The firm has a market cap of $26.69 billion, a PE ratio of 27.22, a price-to-earnings-growth ratio of 1.88 and a beta of 0.87. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. The business has a fifty day moving average of $320.94 and a 200-day moving average of $290.99.

Labcorp (NYSE:LH) last announced its earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same period in the prior year, the business earned $4.35 earnings per share. Labcorp’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, equities research analysts predict that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be given a dividend of $0.72 per share. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. Labcorp’s dividend payout ratio is presently 23.82%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LH. Mizuho set a $355.00 price objective on Labcorp in a research note on Monday, August 10th. Bank of America increased their price objective on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Weiss Ratings upgraded shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday. Piper Sandler lifted their price target on shares of Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. lifted their price objective on Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $337.73.

About Labcorp

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.